Kymera Therapeutics, Inc.
CRYSTALLINE FORMS OF IRAK DEGRADERS
Last updated:
Abstract:
The present disclosure relates generally to various forms, salts and compositions of compounds useful for the modulation of one or more interleukin-1 receptor-associated kinases ("IRAK") via ubiquitination and/or degradation and uses of the same in the treatment various diseases.
Status:
Application
Type:
Utility
Filling date:
3 Jun 2021
Issue date:
23 Dec 2021